New drug combo shows promise against aggressive lung cancer
NCT ID NCT04063163
Summary
This study tested whether adding the experimental drug HLX10 to standard chemotherapy helps people with advanced small cell lung cancer live longer. 585 patients who hadn't received prior treatment were randomly assigned to receive either HLX10 plus chemotherapy or a placebo plus chemotherapy. Researchers compared how long patients lived and how long their cancer stayed controlled between the two groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkhangelsk Clinical Oncology Dispensary
Arkhangelsk, Russia
-
Institute for Personalized Medicine
Tbilisi, Georgia
-
Komunalnyi zaklad Miska bahato
Dnipropetrovsk, Ukraine
-
Medipol Mega Hospital
Istanbul, Turkey (Türkiye)
-
Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologi
Lodz, Poland
Conditions
Explore the condition pages connected to this study.